-

KDDIY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving KDDI Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of KDDI Corporation (“KDDI” or the “Company”) (OTC:KDDIY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On February 6, 2026, KDDI posted an announcement on its website entitled “Notice Regarding Expectation that Disclosure of Earnings Report for the Third Quarter of the Fiscal Year Ending March 2026 Will Exceed the 45-Day Period Following the End of Such Quarter.” The announcement stated that KDDI has “decided to postpone the disclosure of its earnings report” and that the reason for postponement was due to uncertainties regarding the quarterly results, in light of a previously announced internal investigation. On this news, the price of KDDI shares declined by $2.03 per share, or approximately 11.44%, from $17.74 per share on February 5, 2026 to close at $15.71 on February 6, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired KDDI securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

Pink Limited:KDDIY

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

LCID INVESTOR REMINDER: Lucid Group, Inc. Investors Have Until July 28, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until July 28, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. Th...

INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) securities during the period of January 14, 2025 through April 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Erasca investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...

INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).If you suffered a loss on your ADMA investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...
Back to Newsroom